MorphoSys (MOR) Given a €120.00 Price Target by JPMorgan Chase & Co. Analysts

MorphoSys (ETR:MOR) received a €120.00 ($139.53) price objective from JPMorgan Chase & Co. in a research note issued to investors on Friday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 28.69% from the stock’s current price.

MOR has been the topic of a number of other reports. Independent Research set a €96.00 ($111.63) price target on shares of MorphoSys and gave the company a “neutral” rating in a research note on Thursday, March 14th. Berenberg Bank set a €108.00 ($125.58) price target on shares of MorphoSys and gave the company a “neutral” rating in a research note on Thursday, February 28th. Deutsche Bank set a €125.00 ($145.35) price target on shares of MorphoSys and gave the company a “buy” rating in a research note on Tuesday, January 29th. Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the company a “neutral” rating in a research note on Friday, January 18th. Finally, Royal Bank of Canada set a €65.00 ($75.58) price target on shares of MorphoSys and gave the company a “sell” rating in a research note on Thursday, March 14th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of €100.78 ($117.18).

Shares of MorphoSys stock opened at €93.25 ($108.43) on Friday. The stock has a market capitalization of $2.94 billion and a P/E ratio of -50.16. MorphoSys has a twelve month low of €76.45 ($88.90) and a twelve month high of €124.90 ($145.23). The company has a debt-to-equity ratio of 8.65, a quick ratio of 7.53 and a current ratio of 7.75.

About MorphoSys

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

See Also: The Role of a Fiduciary and Individual Investors

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.